Overview

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effectiveness of REGN475 compared to placebo in participants with pain due to osteoarthritis (OA) of the knee or hip and a history of inadequate joint pain relief or intolerance to current analgesic therapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Regeneron Pharmaceuticals
Treatments:
Fasinumab